Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer's licensing deal with China's 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what Merck paid last year for its deal with China's LaNova Pfizer Inc. plans to spend ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...